Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques

Blood

Volumn 100, Issue 5, 2002, Pages 1662-1669

  Nathwani, Amit C ^a,b,c,d,e   Davidoff, Andrew M ^a,b,c,d,e   Hanawa, Hideki ^a,b,c,d,e   Hu, Yunyu ^a,b,c,d,e   Hoffer, Fredric A ^a,b,c,d,e   Nikanorov, Alexander ^a,b,c,d,e   Slaughter, Clive ^a,b,c,d,e   Ng, Catherine Y C ^a,b,c,d,e   Zhou, Junfang ^a,b,c,d,e   Lozier, Jay N ^a,b,c,d,e   Mandrell, Timothy D ^a,b,c,d,e   Vanin, Elio F ^a,b,c,d,e   Nienhuis, Arthur W ^a,b,c,d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b National Blood Authority   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; HYPERIMMUNE GLOBULIN; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEMOPHILIA B; HEPATIC ARTERY; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RHESUS MONKEY; SOUTHERN BLOTTING;

EID: 0036721008     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0589     Document Type: Article

References (44)

1. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
2. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
3. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
4. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
5. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
6. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
7. Persistent expression of canine factor IX in hemophilia B canines
8. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA
9. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus FIX
10. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation
11. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9
12. Induction of immunological tolerance to a coagulation factor antigen by hepatic gene transfer
13. + T cells results in antigen-specific T-cell tolerance
14. Trial halted after gene shows up in semen
15. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males
16. Targeted integration of adeno-associated virus (AAV) into human chromosome 19
17. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates
18. The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan
19. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
20. Transduction of hematopoietic stem cells in humans and in nonhuman primates
21. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses
22. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
23. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
24. Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells
25. The rhesus macaque as an animal model for hemophilia B gene therapy
26. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
27. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses
28. - subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV
29. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
30. Coagulation factor VII Gln 100→Arg: Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function
31. Human factor IX corrects the bleeding diathesis of mice with hemophilia B
32. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction
33. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
34. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
35. Immune responses to adenovirus and adeno-associated virus in humans
36. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model
37. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen
38. Antigen-specific T cell activation and proliferation during oral tolerance induction
39. Epidemiology of coagulation disorders
40. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)
41. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
42. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo
43. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle
44. A proposed rAAV-liver directed clinical trial for hemophilia B